What are Exelixis's main products?
Exelixis, Inc. is an oncology-focused biotechnology enterprise dedicated to discovering, developing, and commercializing innovative medicines for difficult-to-treat cancers. Its primary flagship commercial product is CABOMETYX (cabozantinib), an oral small-molecule tyrosine kinase inhibitor approved for treating advanced renal cell carcinoma, hepatocellular carcinoma, neuroendocrine tumors, and previously treated advanced conditions. Other marketed products include COMETRIQ capsules for progressive metastatic medullary thyroid cancer and COTELLIC (cobimetinib), a targeted MEK inhibitor utilized in combination regimens for advanced melanoma.
Related FAQs
Exelixis, Inc. is an American commercial-stage biopharmaceutical enterprise headquartered in Alameda, California, dedicated to the discovery, development, and commercialization of innovative medicines for the treatment of difficult-to-treat cancers.
Exelixis, Inc. (NASDAQ: EXEL) trades at $55.06 per share, supported by a robust market capitalization of approximately $13.84 billion.
Long-term institutional models and analyst projections looking toward 2030 for Exelixis, Inc.
Axcelis Technologies maintains a solid future outlook anchored by its strong technological leadership in ion implantation equipment essential for semiconductor device manufacturing, power chips, and advanced memory architectures.
Assessing whether Novo Nordisk equity is an attractive purchase currently involves analyzing its leadership position in the booming metabolic disease and weight-management pharmaceutical market.
Exelon Corporation, one of the largest utility companies in the United States, holds a generally stable reputation as a reliable provider of electricity to millions of customers.
Whether Exelixis (EXEL) is a good stock to buy is a decision that should be based on your personal investment objectives and risk appetite.
Yes, Exelixis has demonstrated strong commercial performance and financial health, largely driven by its oncology drug Cabometyx [1.1.1].
As of July 2026, Exelixis (EXEL) maintains a "Buy" consensus rating among analysts. The company's stock has demonstrated a strong multi-year performance record, supported by consistent revenue and cash flow from its oncology treatments.
Based on the consensus of 14 analysts as of July 24, 2026, Exelixis (EXEL) holds a "Buy" rating. This professional sentiment is driven by the company's historical earnings performance and its role in the biotechnology sector.
Wall Street analysts tracking Exelixis generally maintain optimistic outlooks, driven by strong clinical pipeline developments and steady commercial revenue growth from its flagship oncology treatments.
Yes, Exelixis is a U.S.-based oncology biopharmaceutical company [1.2.1]. Founded in 1994 and headquartered in Alameda, California, its primary commercial and organizational operations are centered within the United States [1.2.1].
Exelixis is a biopharmaceutical company primarily known for its oncology research and the development of small-molecule medicines for the treatment of cancer.
Exelixis, Inc. (EXEL) is a successful commercial-stage biotechnology company focused on the discovery, development, and commercialization of innovative medicines for difficult-to-treat cancers, anchored by its flagship drug cabozantinib.